MDx/CDx Focus: Austin Breast Center Offers BrevaGen; Epigenomics Studies Colon Cancer MDx vs FIT
April 11, 2012
MDx/CDx Focus: Austin Breast Center Offers BrevaGen; Epigenomics Studies Colon Cancer MDx vs FIT
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- ARUP Launches Blood-Based LDT for Colorectal Cancer in US Based on Epigenomics' Septin9 Biomarker
July 22, 2010 / PCR Insider - MDx/CDx Focus: Epigenomics Septin9 Deal; BRCA MASTR Dx Gets CE Mark; Xalkori Phase III Study Results
June 19, 2012 / Pharmacogenomics Reporter - Epigenomics Files Third Module of PMA to FDA for Colon Cancer Test
June 12, 2012 / GenomeWeb Daily News - MDx/CDx Focus: Another CDx Deal for Dako, Amgen; NYDOH Clears Enzo to Market ColonSentry
February 22, 2012 / Pharmacogenomics Reporter - Qiagen Building Sample-Prep Tech for Colorectal Cancer Test Under Epigenomics Option
March 3, 2011 / PCR Insider